Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal ...

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...